SAB Biotherapeutics (NASDAQ:SABS) Lowered to Sell Rating by Wall Street Zen

SAB Biotherapeutics (NASDAQ:SABS) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

SABS has been the subject of several other reports. HC Wainwright lowered their target price on SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday. Chardan Capital boosted their price target on SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings reissued a “sell (d)” rating on shares of SAB Biotherapeutics in a report on Monday, December 29th. Guggenheim assumed coverage on SAB Biotherapeutics in a research note on Friday, December 19th. They set a “buy” rating and a $15.00 price objective for the company. Finally, UBS Group initiated coverage on SAB Biotherapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $7.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

SAB Biotherapeutics Trading Down 9.6%

NASDAQ SABS opened at $4.15 on Friday. The stock has a market cap of $211.44 million, a P/E ratio of -1.79 and a beta of 0.59. The company’s fifty day simple moving average is $4.02 and its 200-day simple moving average is $3.36. The company has a current ratio of 9.46, a quick ratio of 10.50 and a debt-to-equity ratio of 0.02. SAB Biotherapeutics has a 52 week low of $1.00 and a 52 week high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.30). Equities research analysts predict that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of hedge funds have recently bought and sold shares of the company. ADAR1 Capital Management LLC bought a new stake in SAB Biotherapeutics in the third quarter valued at about $30,000. Dimensional Fund Advisors LP bought a new position in SAB Biotherapeutics during the 3rd quarter worth approximately $32,000. State of Wyoming acquired a new position in shares of SAB Biotherapeutics in the 4th quarter worth approximately $34,000. Virtu Financial LLC bought a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at approximately $40,000. Finally, State Street Corp bought a new stake in shares of SAB Biotherapeutics in the 4th quarter valued at approximately $49,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.